1. Bast, R.C., Jr., Klug, T.L., St. John, E., Jenison, E., Niloff, J.M., Lazarus, H., Berkowitz, R.S., Leavitt, T., Griffiths, C.T., Parker, L., Zurawski, V.R., Jr., and Knapp, R.C., N. Engl. J. Med., 1983, vol. 309, pp. 883–887.
2. Klug, T.L., Bast, R.C., Jr., Niloff, J.M., Knapp, R.C., and Zurawski, V.R., Jr.., Cancer Res., 1984, vol. 44, pp. 1048–1053.
3. Anastasi, E., Marchei, G.G., Viggiani, V., Gennarini, G., Frati, L., and Reale, M.G., Tumour Biol., 2010, vol. 31, pp. 113–119.
4. U.S. Food and Drug Administration (FDA), 510(k) Substantial Equivalence Determination Decision Summary: OVA1™ Test (K081754). http://www.accessdata. fda.gov/cdrh_docs/reviews/K081754.pdf (Accessed October 15, 2015).
5. Escudero, J.M., Auge, J.M., Filella, X., Torne, A., Pahisa, J., and Molina, R., Clin. Chem., 2011, vol. 57, pp. 1534–1544.